| Company Name | Novartis (Taiwan) Co., Ltd |
|---|---|
| Protocol Number | CINC424ATW01 |
| Title of Study | Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk of Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), or Post-essential Thrombocythemia Myelofibrosis (PET-MF) |
| Primary Objective | To evaluate the safety profile of ruxolitinib in patients with intermediate-2 or high-risk PMF, PPV-MF, or PET-MF under routine clinical practice |
| Number of Sites | 10 |
| Period of Study | From：Jan 2017 to：Jan 2021 |
| Number of Patients | 100人 |
| IRB Approval Date | 27 Dec 2016 (first site) |
| Publication Plan / Date | Jul 2022 |
